A composition, its method of preparation and use in improving brain health

Abstract

The present application relates to the technical field of biotechnology, and particularly discloses a composition, a preparation method thereof and application in improving brain health. The present application finds that when oat green extract and sialic acid are combined in a specific ratio, the composition can simultaneously have the effects of promoting brain development and improving cognitive impairment in the elderly, and further proposes a composition comprising: oat green extract and sialic acid; the mass ratio of the oat green extract and the sialic acid is (0.7-41.5):(1-14). The composition of the present application can simultaneously promote brain development and improve cognitive impairment in the elderly, and provides an effective new solution capable of acting throughout the entire life cycle for improving brain health.

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and more specifically, to a composition, a method for preparing the same, and its application in improving brain health. Background Technology

[0002] Oat extract is made from the whole aerial parts (stems and leaves) of immature oats (Latin name Avena sativa L., genus Avena in the family Poaceae) through processes such as extraction with 30% ethanol, concentration, drying, and grinding. Its main nutrients include carbohydrates, proteins, and fats.

[0003] Oat extract, primarily derived from the aerial parts of wild oats, has cognitive-enhancing effects supported by some clinical studies. Its mechanisms of action include regulating the neurotransmitter system, improving cerebral blood flow and energy metabolism, and exhibiting anti-inflammatory and antioxidant properties to enhance cognition. Current research mainly focuses on acute cognitive improvements in healthy adults (19-65 years old) (such as improved attention under stress), but research on its brain-developing functions during the developmental stage is insufficient.

[0004] Sialic acid (Sia / SA) is a key component of gangliosides and glycoproteins, particularly abundant in breast milk, and its mechanism of action is well-defined: as an important component of nerve cell membranes and synapses, it directly participates in neuronal migration, axonal growth, and the regulation of synaptic plasticity, especially crucial during the rapid brain development period of infants and young children; it influences the expression of genes related to learning and memory; it indirectly supports neural development by inhibiting pathogen adsorption and regulating gut microbiota; and it may also delay neurodegenerative diseases through anti-inflammatory mechanisms. The primary evidence for the role of sialic acid in brain health comes from studies on infant brain development.

[0005] Currently, nutritional research on early-life brain development and age-related cognitive decline are two relatively independent fields. No research has yet revealed whether the combined use of multiple components can exert cognitive-enhancing effects across the entire lifespan, in both distinct physiological / pathological states. Summary of the Invention

[0006] One of the objectives of this invention is to provide a novel composition that can maintain cognitive health (brain health) from early life to old age.

[0007] The present invention provides a composition comprising: oat green extract and sialic acid; wherein the mass ratio of oat green extract to sialic acid is (0.7-41.5):(1-14), preferably (0.7-41.3):(1-14).

[0008] Currently, the combined use of sialic acid with ingredients such as DHA, theanine, and phosphatidylserine is quite common, with functions mainly focused on intellectual development and memory improvement. Research on oat green extract has primarily focused on acute cognitive improvement. However, this study found that when oat green extract and sialic acid are combined in a specific ratio, they produce a synergistic effect in both promoting brain development and improving age-related cognitive impairment. This breaks away from existing compositions that only target one of the two effects—promoting brain development or improving age-related cognitive impairment—and unexpectedly provides an effective composition that simultaneously promotes brain development and improves age-related cognitive impairment, offering a new approach to improving brain health that can be effective throughout the entire lifespan.

[0009] If other known brain-health-enhancing components are used in combination with oat extract or sialic acid in the combination of the present invention, the desired effect cannot be achieved. For example, in Comparative Example 3, sialic acid was combined with theanine, and in Comparative Example 4, oat extract was combined with phosphatidylserine. These combinations are not only less effective in promoting brain development than the present invention, but also less effective in improving age-related cognitive impairment.

[0010] If the focus is more on achieving the desired effect of promoting brain development, it is preferred that the mass ratio of oat green extract to sialic acid is (0.7-41.5):(1-1.5), more preferably (0.7-41.3):(1-1.5), and even more preferably 0.7:(1-1.5).

[0011] If the focus is more on achieving the desired effect of improving age-related cognitive impairment, the mass ratio of oat extract to sialic acid is preferably (0.7-10):(1-5), more preferably (0.7-9.8):(1-5), and even more preferably 0.7:(1-3).

[0012] In summary, the optimal solution for all aspects of efficacy is a mass ratio of oat green extract to sialic acid of 0.7:1.

[0013] The present invention also provides a method for preparing the above composition, which includes the step of mixing oat extract and sialic acid.

[0014] Those skilled in the art can use methods known in the art to mix oat green extract and sialic acid, and the present invention does not limit this.

[0015] The present invention also provides the use of the above composition in the preparation of products that improve brain health.

[0016] In the application of this invention, improving brain health refers to promoting brain development and / or improving age-related cognitive impairment.

[0017] The present invention also provides a product that promotes brain development and / or improves age-related cognitive impairment, comprising the above-described composition.

[0018] The active ingredients in the product may be only the composition described above in this invention, or may also include other active ingredients.

[0019] For example, the product may be a pharmaceutical product, which may include pharmaceutically acceptable excipients known in the art; the dosage form may be a tablet, capsule, granule, powder, pill, oral solution, syrup, emulsion, suspension, drop pill, enteric-coated preparation, or other pharmaceutical dosage forms known in the art.

[0020] The beneficial effects of this invention are at least as follows:

[0021] This invention combines oat green extract and sialic acid in a specific ratio to provide a novel composition that can simultaneously promote brain development and improve age-related cognitive impairment, offering a new approach to improving brain health that can be effective throughout the entire life cycle. Attached Figure Description

[0022] Figure 1 The percentage of movement in the blue area of ​​zebrafish after different sample treatments.

[0023] Figure 2 Genes related to promoting brain development bdnf Relative expression levels. Specifically, compared to the normal control group, P < 0.001; Compared with the oat extract group, P < 0.01, P < 0.001; Compared with the sialic acid group, P < 0.01, P < 0.001.

[0024] Figure 3 Genes related to promoting brain development gdnfa Relative expression levels. Specifically, compared to the normal control group, P < 0.001; Compared with the oat extract group, P < 0.05, P < 0.001; Compared with the sialic acid group, P < 0.05, P < 0.001.

[0025] Figure 4 The percentage of blue region movement in zebrafish after different sample treatments (aging-related cognitive model).

[0026] Figure 5The values ​​represent the average staining intensity of β-galactosidase. Compared to the model control group, P < 0.05 P < 0.01 P < 0.001; compared with the oat green extract group, P < 0.05.

[0027] Figure 6 This represents the telomerase activity in zebrafish. Compared to the model control group, P < 0.05 P < 0.001; Compared with the oat extract group, &: P < 0.05, &&&: P < 0.001; Compared with the sialic acid group, #: P < 0.05, ##: P < 0.01. Detailed Implementation

[0028] The preferred embodiments of the present invention will now be described in detail with reference to specific examples. It should be understood that the following examples are given for illustrative purposes only and are not intended to limit the scope of the invention. Those skilled in the art can make various modifications and substitutions to the present invention without departing from its spirit and essence.

[0029] Unless otherwise specified, the experimental methods used in the following examples are conventional methods. Unless otherwise specified, the materials and reagents used in the following examples can be obtained commercially or prepared according to conventional methods in the art. The oat extract described in the Specific Embodiments section of this invention was purchased from IFF Health Sciences, traded as Neuravena® Oat Extract (trade name in China: Oat Extract Solid Beverage). The active ingredient, oat extract, contains 70% (in the following examples and comparative examples, when using this raw material, its mass ratio needs to be multiplied by 70% to obtain the mass ratio of the active ingredient; for example, in Example 2, the mass ratio of oat extract to sialic acid is 5:1, which, after conversion, results in a mass ratio of 3.5:1 for the two active ingredients). Sialic acid was purchased from Jiabiyou Biotechnology (Wuhan) Co., Ltd., traded as N-acetylneuraminic acid. It is produced from food-grade glucose and corn steep liquor through processes such as Escherichia coli (strain number SA-8) fermentation, filtration, sterilization, hydrolysis, and purification. Phosphatidylserine was purchased from Beijing Yifan International Trade Co., Ltd., produced by IFF, and marketed under the trade name Sharp PS®60P-FP CNPCN. It is a powdered phosphatidylserine product, with soybean lecithin as its main raw material and a PS content of 60%. Theanine was purchased from Huisong Pharmaceutical, marketed under the trade name Tea Theanine. It is a yellow-brown amorphous powder extracted from tea leaves.

[0030] Example 1

[0031] This embodiment provides a composition comprising oat green extract and sialic acid in a mass ratio of 59:1. During preparation, the components are uniformly mixed in the specified proportions.

[0032] Example 2

[0033] This embodiment provides a composition comprising oat green extract and sialic acid in a mass ratio of 5:1. During preparation, the components are uniformly mixed in the specified proportions.

[0034] Example 3

[0035] This embodiment provides a composition comprising oat green extract and sialic acid in a mass ratio of 3:1. During preparation, the components are uniformly mixed in the specified proportions.

[0036] Example 4

[0037] This embodiment provides a composition comprising oat green extract and sialic acid in a 1:1 mass ratio. During preparation, the components are uniformly mixed in the specified proportions.

[0038] Example 5

[0039] This embodiment provides a composition comprising oat green extract and sialic acid in a mass ratio of 1:1.5. During preparation, the components are uniformly mixed in the specified proportions.

[0040] Example 6

[0041] This embodiment provides a composition comprising oat green extract and sialic acid in a mass ratio of 1:14. During preparation, the components are uniformly mixed in the specified proportions.

[0042] Example 7

[0043] This embodiment provides a composition comprising oat green extract and sialic acid in a mass ratio of 14:1. During preparation, the components are uniformly mixed in the specified proportions.

[0044] Example 8

[0045] This embodiment provides a composition comprising oat green extract and sialic acid in a mass ratio of 1:3. During preparation, the components are uniformly mixed in the specified proportions.

[0046] Example 9

[0047] This embodiment provides a composition comprising oat green extract and sialic acid in a mass ratio of 1:5. During preparation, the components are uniformly mixed in the specified proportions.

[0048] Comparative Example 1

[0049] This comparative example provides a composition comprising oat green extract and sialic acid in a mass ratio of 1:99. During preparation, the components are uniformly mixed in the specified proportions.

[0050] Comparative Example 2

[0051] This comparative example provides a composition comprising oat green extract and sialic acid in a mass ratio of 299:1. During preparation, the components are uniformly mixed in the specified proportions.

[0052] Comparative Example 3

[0053] This comparative example provides a composition comprising theanine and sialic acid in a mass ratio of 1:1. During preparation, the components are uniformly mixed in the specified proportions.

[0054] Comparative Example 4

[0055] This comparative example provides a composition comprising oat green extract and phosphatidylserine (PS) in a mass ratio of 1:1. During preparation, the components are uniformly mixed in the specified proportions.

[0056] Comparative Example 5

[0057] This comparative example provides a composition comprising oat green extract and sialic acid in a mass ratio of 99:1. During preparation, the components are uniformly mixed in the specified proportions.

[0058] Experiment 1 promotes brain development

[0059] This experimental example verifies the brain development (cognitive enhancement) efficacy (indicator: percentage of motor activity in the blue area) of the above-described embodiments and comparative examples.

[0060] Color preference tests are frequently used in cognitive assessments of zebrafish. Zebrafish prefer shorter wavelengths of color, and compared to other colors (such as red, yellow, and green), they exhibit a strong preference for blue. This preference becomes more pronounced as the brain develops. In other words, the more movement a zebrafish makes in the blue area, the more cognitively mature its cognitive abilities.

[0061] Experimental Methods: Wild-type AB strain zebrafish, 5 days post-fertilization (5 dpf), were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Water-soluble samples were administered (concentrations of each substance are shown in Table 1). Edaravone was used as the positive control at a concentration of 5.00 μg / mL. A normal control group and groups treated with oat extract or sialic acid alone were also included. Each beaker had a volume of 20 mL. After treatment at 28℃ for 1 day, zebrafish from each experimental group were randomly placed into "+" modules, which were divided into four areas: yellow, blue, red, and green. Six modules were placed in each group, with five zebrafish in each module. Data were collected using a behavior analyzer, and the percentage (%) of the total movement distance of the zebrafish within the blue area relative to the total movement distance of the entire area within 10 minutes was analyzed. This yielded six parallel experimental data points for each group (each data point was the sum of the test results of five fish in a single module). The statistical analysis results of this index were used to evaluate the efficacy of the sample in promoting brain development. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and p < 0.05 was considered statistically significant.

[0062] The experimental results are shown in Table 1 and Figure 1 :

[0063] Compared with non-compound components, the present invention has a more significant effect on promoting brain development at the same dosage. Moreover, the preferred solution (oat green extract: sialic acid = 1:1) shows a significant increase in the proportion of movement in the blue area at the same dosage compared with other embodiments and comparative examples.

[0064] Table 1. Experimental results of the samples' effects on promoting brain development (enhancing cognition) (n=6)

[0065]

[0066] Table 1 shows the comparison with the normal control group. p<0.05, p<0.01, p<0.001, p<0.0001; compared with the oat green extract: sialic acid 1:1 group, #, P<0.05, ##, P<0.01.

[0067] Under the experimental conditions, all examples and comparative examples demonstrated the effect of promoting brain development (enhancing cognition), with the examples showing better results. Example 4 exhibited the best efficacy, significantly improving the efficacy compared to groups treated with oat extract or sialic acid alone. If other brain-health-promoting components were substituted for oat extract (Comparative Example 3) or sialic acid (Comparative Example 4), the overall efficacy significantly decreased.

[0068] Synergistic efficacy analysis was performed on several compositions with different ratios. The difference between the observed and expected effect values ​​(ΔE) was calculated using the Bliss independent model. ΔE > 0 indicated synergy, ΔE < 0 indicated antagonism, and ΔE = 0 indicated an additive effect. The results are shown in Table 2. It can be seen that oat extract:sialic acid exhibits a synergistic effect when the ratio ranges from 59:1 to 1:14, with the strongest synergistic effect observed at a ratio of 1:1.

[0069] Table 2 Synergistic effect analysis of different proportions of the composition

[0070]

[0071] Example 2: Expression of genes related to brain development.

[0072] bdnfa and its receptors are widely expressed in the nervous system, with the highest content in the hippocampus and cortex. Their specific mechanisms of action in the central nervous system are as follows: (1) increasing synaptic plasticity, thereby affecting long-term potentiation (nLTP), which is the basis for learning and memory formation (secondary memory); (2) promoting neurogenesis, especially in the hippocampus; (3) promoting cell survival, mainly manifested in maintaining and promoting the development, differentiation, growth, and regeneration of various neurons, especially serotonin (5-HT) and dopaminergic (DA) neurons. Meanwhile, gdnfa can promote the survival of different neuronal subsets at different stages of development in both the central and peripheral nervous systems, supporting the generation of type I astrocytes, neuronal membrane cells, neurons, pineal gland cells, etc., especially showing significant survival-promoting efficiency for spinal motor neurons. Therefore, genes... bdnf The upregulation of gdnfa expression indicates that the sample has the effect of promoting brain development.

[0073] Experimental Methods: Wild-type AB strain zebrafish (5 dpf) were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Water-soluble samples were administered (concentrations of each substance are listed in Table 1 for the same group). Edaravone was used as the positive control at a concentration of 5.00 μg / mL. A normal control group and groups treated with oat extract or sialic acid alone were also included. Each beaker had a volume of 20 mL. After treatment at 28℃ for 1 day, total RNA was extracted from each group of zebrafish using a pre-loaded magnetic bead-based universal RNA extraction kit (batch number TL2402001643C, ONREW, China). The concentration and purity of total RNA were determined using a UV-Vis spectrophotometer. 2.00 μg of total RNA from the zebrafish sample was used to synthesize 20.0 μL of cDNA according to the instructions of a cDNA first-strand synthesis kit (batch number H9305270, Yisheng Biotechnology (Shanghai) Co., Ltd., China). The cDNA was then detected by q-PCR. β-actin , bdnf and gdnfa Gene expression. Using β-actin as an internal reference for gene expression, calculations were performed. bdnf and gdnfa Relative RNA expression levels of genes. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software; p < 0.05 was considered statistically significant.

[0074] See results Figure 2 and Figure 3 Under the experimental conditions, all embodiments and comparative examples demonstrated the effect of promoting brain development, specifically by upregulating... bdnf Genes and gdnfa Relative gene expression levels. The efficacy of each embodiment was superior, and significantly improved compared to groups treated with oat green extract or sialic acid alone.

[0075] Experiment Example 3: Efficacy in improving age-related cognitive impairment (Indicator: Cross-shaped maze)

[0076] At higher doses, D-galactose (D-gal) is converted into aldoses and hydroperoxides by galactose oxidase, forming superoxide anions and oxygen-derived free radicals. This can inhibit cellular defenses, increase lipid peroxidation, and release end products that react with proteins and phospholipids, leading to cell damage and central nervous system damage. Simultaneously, it causes an abnormal increase in malondialdehyde concentration in the brain, inducing abnormal neurotoxicity from advanced glycation end products, resulting in behavioral and neurochemical changes. Sleep deprivation can lead to autonomic nervous system dysfunction, manifesting as palpitations, chest tightness, decreased appetite, and weight gain, all of which accelerate the aging process. It also causes an imbalance in neurotransmitter secretion in the brain, affecting brain activity and nerve function, potentially leading to neurasthenia, depression, anxiety, and other mental illnesses. People with chronic sleep deprivation are prone to mental health problems such as poor concentration, cognitive impairment, memory loss, and mood swings; therefore, combining oxidative stimulation with physical stimulation can indirectly accelerate the aging process.

[0077] Color preference tests are frequently used in the cognitive assessment of zebrafish. Zebrafish prefer short-wavelength colors, and compared to other colors (such as red, yellow, and green), they show a strong preference for blue. When zebrafish exhibit aging accompanied by cognitive impairment, their cognitive abilities decline, and their preference for blue weakens. A blue area movement ratio between the model control group and the normal control group is considered a successful model establishment if it falls within the range of 0.25 to 0.75.

[0078] Experimental methods:

[0079] An experiment was conducted using a zebrafish aging and cognitive impairment model induced by D-galactose combined with sleep deprivation.

[0080] Wild-type AB strain zebrafish, 3 days post-fertilization (3 dpf), were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Water-soluble samples were administered (concentrations of each substance are shown in Table 3). The positive control was ginseng stem and leaf total saponins tablets at a concentration of 100 μg / mL. A normal control group, groups treated with oat extract or sialic acid alone, and a model control group were also included. Each beaker had a volume of 20 mL. Except for the normal control group, all other experimental groups were given water-soluble D-galactose 12.8 mg / mL combined with physical stimulation (water rotation at 1500 rpm) to induce a zebrafish aging and cognitive impairment model. After treatment at 28℃ for 2 days, zebrafish were randomly selected from each experimental group and placed into a cross maze. The maze was divided into four areas: yellow, blue, red, and green. Six mazes were placed in each group, with five zebrafish in each module. Data was collected using a behavior analyzer, and the percentage (%) of the total distance the zebrafish traveled within the blue area relative to the total distance traveled in the entire area within 10 minutes was analyzed. This yielded six parallel experimental data points for each group (each data point being the sum of the test results of five fish in a single module). The statistical analysis results of this indicator were used to evaluate the efficacy of the sample in improving age-related cognitive impairment (cross maze). Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and p < 0.05 indicated statistical significance.

[0081] The experimental results are shown in Table 3 and Figure 4 :

[0082] Compared with non-compound components, the present invention has a more significant effect on improving age-related cognitive impairment at the same dosage. Moreover, the preferred solution (oat green extract: sialic acid = 1:1) shows a significant increase in the proportion of movement in the blue area at the same dosage compared with other embodiments and comparative examples.

[0083] Table 3. Experimental results on the efficacy of the samples in improving aging-related cognitive impairment (n = 6)

[0084]

[0085] Table 3 shows the comparison with the normal control group. p<0.05, p<0.01, p<0.001, P<0.0001; compared with the oat green extract: sialic acid 1:1 group, #, P<0.05.

[0086] Under the experimental conditions, all examples and comparative examples showed efficacy in improving age-related cognitive impairment, with the examples showing better results. Example 4 demonstrated the best efficacy, significantly improving the efficacy compared to groups treated with oat extract or sialic acid alone. If other brain-health-promoting components were substituted for oat extract (Comparative Example 3) or sialic acid (Comparative Example 4), the overall efficacy significantly decreased.

[0087] Synergistic efficacy analysis was performed on several compositions with different ratios. The difference between the observed and expected effect values ​​(ΔE) was calculated using the Bliss independent model. ΔE > 0 indicated synergy, ΔE < 0 indicated antagonism, and ΔE = 0 indicated an additive effect. The results are shown in Table 4. It can be seen that oat extract:sialic acid exhibits a synergistic effect when the ratio is between 59:1 and 1:14, with the strongest synergistic effect observed at a ratio of 1:1.

[0088] Table 4 Synergistic analysis of the efficacy of different proportions of the composition (aging with cognitive impairment)

[0089]

[0090] Experimental Example 4: Efficacy in Improving Age-Related Cognitive Impairment (β-Galactosidase Activity)

[0091] β-galactosidase (SA-β-gal) exhibits high enzyme activity at pH 6.0, a key characteristic of senescent cells and a widely used biomarker for cellular senescence. SA-β-gal is a hydrolytic enzyme within lysosomes, and senescent cells are typically accompanied by an increase in the number and volume of lysosomes. SA-β-gal is believed to be primarily located in lysosomes, and lysosomal amplification directly leads to increased enzyme activity. The β-galactosidase staining kit for cellular senescence uses X-gal as a substrate. In senescent cells, β-galactosidase catalyzes the production of a deep blue product; the deeper the color, the more β-galactosidase-positive cells (senescent cells) are present, and the more severe the senescence. In zebrafish exhibiting aging accompanied by cognitive impairment, the average β-galactosidase staining intensity increases. A mean β-galactosidase staining intensity ratio between the normal control group and the model control group, ranging from 0.60 to 0.93, is considered a successful model preparation.

[0092] Experimental Methods: Wild-type AB strain zebrafish (3 dpf) were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Water-soluble samples were administered (concentrations of each substance are listed in Table 3 for the same group). The positive control was ginseng stem and leaf total saponins tablets at a concentration of 100 μg / mL. A normal control group, groups treated with oat extract or sialic acid alone, and a model control group were also included. Each beaker had a volume of 50 mL. Except for the normal control group, all other experimental groups were given water-soluble D-(+)-galactose 12.8 mg / mL combined with physical stimulation (water rotation at 1500 rpm) to induce a zebrafish aging and cognitive impairment model. After treatment at 28℃ for 2 days, zebrafish from each experimental group were stained using a cellular senescence β-galactosidase staining kit (batch number 031924240704, Shanghai Beyotime Biotechnology Co., Ltd., China). After staining, 10 zebrafish from each experimental group were randomly selected and photographed under a dissecting microscope. Data were collected using NIS-Elements D 3.20 advanced image processing software. The average β-galactosidase staining intensity in zebrafish was analyzed, and the statistical analysis results of this index were used to evaluate the efficacy of the samples in improving aging-related cognitive impairment (β-galactosidase staining). Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software; p < 0.05 indicated statistical significance.

[0093] See results Figure 5 Under the experimental conditions, all examples and comparative examples showed efficacy in improving aging-related cognitive impairment, specifically by inhibiting β-galactosidase activity.

[0094] Experimental Example 5: Efficacy in Improving Age-Related Cognitive Impairment (Telomerase Activity)

[0095] Aging is a process of functional and organic decline in the body during the aging process, including aging-related damage at different levels such as tissues, organs, genes, proteins, cells, and intercellular communication. Specifically, it manifests as telomere shortening, DNA damage accumulation, abnormal oncogene activation, metabolic changes, and the excessive production of reactive oxygen species (ROS). Telomeres, as nucleoprotein structures covering the ends of each chromosome arm, are particularly susceptible to damage caused by age and oxidative stress. When telomeres shorten continuously due to cell division, it exacerbates cell apoptosis and death, ultimately leading to aging. The production of telomerase can slow down the telomere shortening process, thereby delaying aging. In zebrafish exhibiting aging accompanied by cognitive impairment, telomerase activity is reduced. A telomerase activity index between the model control group and the normal control group within the range of 0.20–0.80 is considered a successful model preparation.

[0096] Experimental Methods: Wild-type AB strain zebrafish (3 dpf) were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Water-soluble samples were administered (concentrations of each substance are listed in Table 3 for the same group). The positive control was ginseng stem and leaf total saponins tablets at a concentration of 100 μg / mL. A normal control group, groups treated with oat extract or sialic acid alone, and a model control group were also included. Each beaker had a volume of 50 mL. Except for the normal control group, all other experimental groups were given water-soluble D-(+)-galactose 12.8 mg / mL combined with physical stimulation (water rotation at 1500 rpm) to induce a zebrafish aging and cognitive impairment model. Three parallel experiments were conducted. After treatment at 28℃ for 2 days, zebrafish from each group were cryopreserved in liquid nitrogen. Telomerase activity was detected using the Zebra Fish TEELISA KIT kit (batch number H25Y08, ​​Shanghai Hengyuan Biotechnology Co., Ltd., China). Statistical analysis of this indicator was used to evaluate the efficacy of the samples in improving aging-related cognitive impairment (telomerase activity). Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and p < 0.05 was considered statistically significant.

[0097] See results Figure 6 Under the experimental conditions, all examples and comparative examples showed efficacy in improving aging-related cognitive impairment, specifically by promoting telomerase activity.

[0098] Although the present invention has been described in detail above with general descriptions and specific embodiments, modifications or improvements can be made to it, which will be obvious to those skilled in the art. Therefore, all such modifications or improvements made without departing from the spirit of the present invention fall within the scope of protection claimed by the present invention.

Claims

1. A composition, characterized in that, include: Oat green extract and sialic acid; the mass ratio of the oat green extract to sialic acid is (0.7-41.5):(1-14); the oat green extract is made from the stems and leaves of the immature oat whole plant above ground through extraction with 30% ethanol, concentration, drying and grinding.

2. The composition according to claim 1, characterized in that, The mass ratio of oat extract to sialic acid is (0.7-41.5):(1-1.5).

3. The composition according to claim 2, characterized in that, The mass ratio of oat green extract to sialic acid is 0.7:(1-1.5).

4. The composition according to claim 1, characterized in that, The mass ratio of oat green extract to sialic acid is (0.7-10):(1-5).

5. The composition according to claim 4, characterized in that, The mass ratio of oat extract to sialic acid is 0.7:(1-3).

6. The composition according to any one of claims 1-5, characterized in that, The mass ratio of oat green extract to sialic acid is 0.7:

1.

7. A method for preparing the composition according to any one of claims 1-6, characterized in that, This includes the step of mixing oat green extract and sialic acid.

8. Use of the composition according to any one of claims 1-6 in the preparation of products that improve brain health.

9. The application according to claim 8, characterized in that, The improvement of brain health refers to promoting brain development and / or improving age-related cognitive impairment.

10. A product that promotes brain development and / or improves age-related cognitive impairment, characterized in that, Includes the composition according to any one of claims 1-6.

Images